Posaconazole - A new broad-spectrum triazole;Posaconazol - Ein neues breitspektrum-antimykotikum

Chemotherapie Journal

Volumn 16, Issue 4, 2007, Pages 113-122

  Kratzer, Christina ^a   Graninger, Wolfgang ^a   Presterl, Elisabeth ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Invasive fungal infections; Pharmacokinetics; Posaconazole; Prophylaxis; Salvage therapy; Zygomycetes

Indexed keywords

AMPHOTERICIN B; ASTEMIZOLE; CALCIUM ANTAGONIST; CARBAMAZEPINE; CIMETIDINE; CISAPRIDE; CYCLOSPORIN; DIGOXIN; FLUCONAZOLE; HALOFANTRINE; ITRACONAZOLE; MIDAZOLAM; PHENOBARBITAL; PHENYTOIN; PIMOZIDE; POSACONAZOLE; PRIMIDONE; PYRROLE DERIVATIVE; QUINIDINE; RAPAMYCIN; RIFABUTIN; RIFAMYCIN; TACROLIMUS; TERFENADINE; VINCA ALKALOID;

ABSIDIA; ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; ALTERNARIA; ANEMIA; ANOREXIA; ASPERGILLOSIS; ASPERGILLUS; ASTHENIA; BLASTOMYCES; CANDIDA; CHROMOMYCOSIS; CLINICAL TRIAL; COCCIDIOIDES; COCCIDIOIDOMYCOSIS; CRYPTOCOCCUS; CUNNINGHAMELLA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; EXOPHIALA; FOOD; FOOD DRUG INTERACTION; FUSARIUM; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HEADACHE; HISTOPLASMA; HUMAN; HYPERREFLEXIA; LIVER DYSFUNCTION; LOADING DRUG DOSE; MADURELLA; MUCOR; MUCORMYCOSIS; MYCOSIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; PARESTHESIA; RASH; REVIEW; RHIZOPUS; SCEDOSPORIUM; THROMBOCYTOPENIA; THRUSH;

EID: 35148866953     PISSN: 09406735     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Al-Abdely HM, Najvar LK, Bocanegra R, Graybill JR. Antifungal therapy of experimental cerebral phaeohyphomycosis due to Cladophialophora bantiana. Antimicrob Agents Chemother 2005;49:1701-7.
2. Barchiesi F, Schimizzi AM, Caselli F, Giannini D, et al. Activity of a new antifungal triazole, posaconazole, against Cryptococcus neoformans. J Antimicrob Chemother 2001;48:769-73.
3. Barchiesi F, Spreghini E, Schimizzi AM, Maracci M, et al. Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection. Antimicrob Agents Chemother 2004;48:3312-6.
4. Bartlett MS, Loebenberg D, Shaw MM, Durant PJ, et al. Treatment of Pneumocystis carinii with SCH 56592 in vitro and in vivo. Interscience Conference on Antimicrobial Agents and Chemotherapy 1998;38:470 (Abstract J-67).
5. Cacciapuoti A, Gurnani M, Halpern J, Norris C, et al. Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo. Antimicrob Agents Chemother 2005;49:638-42.
6. Cacciapuoti A, Halpern J, Mendrick C, Norris C, et al. Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection. Antimicrob Agents Chemother 2006;50:2587-90.
7. Cacciapuoti A, Loebenberg D, Corcoran E, Menzel F, et al. In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother 2000;44:2017-22.
8. Carrillo-Munoz AJ, Quindos G, Ruesga M, Alonso R, et al. Antifungal activity of posaconazole compared to fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections. J Antimicrob Chemother 2005;55:317-9.
9. Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 2002;15:569-74.
10. Connolly P, Wheat LJ, Schnizlein-Bick C, Durkin M, et al. Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice. Antimicrob Agents Chemother 2000;44:2604-8.
11. Cornely OA, Maertens J, Winston DJ, Perfect J, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59.
12. rd European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, Scotland, May 10-13, 2000.
13. Courtney R, Pai S, Laughlin M, Lim J, et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003;47:2788-95.
14. Courtney R, Sansone A, Smith W, Marbury T, et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol 2005;45:185-92.
15. rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 14-17, 2003.
16. Courtney R, Wexler D, Radwanski E, Lim J, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004;57:218-22.
17. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, et al. Head-to-head comparison for the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006;50:917-21.
18. Dannaoui E, Meis JFGM, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother 2003;47:3647-50.
19. Ezzet F, Wexler D, Courtney R, Krishna G, et al. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005;44:211-20.
20. Ghosal A, Hapangama N, Yuan Y, AchanfuoYeboah J, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos 2004;32:267-71.
21. Gonzalez GM, Tijerina R, Najvar LK, Bocanegra R, et al. In vitro and in vivo activities of posaconazole against Coccidioides immitis. Antimicrob Agents Chemother 2002;46:1352-6.
22. Gonzalez GM, Tijerina R, Najvar LK, Bocanegra R, et al. Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays. Antimicrob Agents Chemother 2003;47:1436-8.
23. Graybill JR, Hernandez S, Bocanegra R, Najvar LK. Antifungal therapy of murine Aspergillus terreus infection. Antimicrob Agents Chemother 2004;48:3715-9.
24. Graybill JR, Najvar LK, Johnson E, Bocanegra R, et al. Posaconazole therapy of disseminated phaeohyphomycosis in a murine model. Antimicrob Agents Chemother 2004;48:2288-91.
25. Greenberg RN, Mullane K, van Burik JAH, Raad II, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006;50:126-33.